Merck Tbk PT
IDX:MERK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (15.1), the stock would be worth Rp11 891.56 (183% upside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 5.3 | Rp4 200 |
0%
|
| 3-Year Average | 15.1 | Rp11 891.56 |
+183%
|
| 5-Year Average | 12.5 | Rp9 833.29 |
+134%
|
| Industry Average | 23.4 | Rp18 435.22 |
+339%
|
| Country Average | 12.6 | Rp9 937.51 |
+137%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| ID |
|
Merck Tbk PT
IDX:MERK
|
1.9T IDR | 5.3 | 7.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 61.3 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 36.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 9.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 12.2 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 24.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 24.3 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 37.8 | 4 516.9 |
Market Distribution
| Min | 0.7 |
| 30th Percentile | 8.6 |
| Median | 12.6 |
| 70th Percentile | 24 |
| Max | 1 806 198.3 |
Other Multiples
Merck Tbk PT
Glance View
PT Merck Tbk engages in the pharmaceutical and chemical businesses. The company is headquartered in Jakarta Timur, Dki Jakarta and currently employs 384 full-time employees. The firm is also engaged in the business of leasing and property management. The Company’s segments include Cardiovascular, Metabolic, Oncology, Endocrinology, Fertility, Neurodegenerative and General Medicines. The Cardiovascular segment provides a range of products, including Amcor, Concor and Lodoz. The Metabolic segment provides a range of products, including Glucophage, Glucophage XR, Glucovance Euthyrox and Thyrozol. The Oncology provides Erbitux product. The Endocrinology provides Saizen product. The Fertility segments include Gonal-F, Pergoveris, Cetrotide, Crinone and Ovidrel products. The Neurodegenerative provides Rebif product. The General Medicines segment provides Encephabol, KSR, Biocream, Praxilene and Stilamin products.
